Welcome to our dedicated page for Strata Critical Medical news (Ticker: SRTA), a resource for investors and traders seeking the latest updates and insights on Strata Critical Medical stock.
News about Strata Critical Medical, Inc. (Nasdaq: SRTA) focuses on its role in time-critical logistics and medical services for the U.S. healthcare and organ transplant industries. Company announcements highlight developments in its organ transport network, integrated organ recovery platform and specialized clinical services delivered through brands such as Trinity Medical Solutions and Keystone Perfusion.
Investors following SRTA news can expect updates on topics the company emphasizes in its communications, including acquisition activity, integration milestones and strategic shifts such as the divestiture of its Passenger business and rebranding from Blade Air Mobility to Strata Critical Medical. Press releases also cover events like Investor Day presentations at the Nasdaq MarketSite and conference appearances, where management discusses its financial framework and business strategy.
Operational news often addresses performance in air and ground logistics for organ transport, growth in organ placement services and expansion of normothermic regional perfusion and perfusion staffing offerings. The company’s updates may also describe how acquisitions like Keystone Perfusion contribute to creating a full-service organ transplant and cardiovascular care platform, as well as efforts to broaden services into other medical sectors.
For readers tracking SRTA, this news stream offers insight into how Strata is shaping its organ logistics and medical services platform, how it characterizes its market position and risk factors, and how management presents its non-GAAP metrics and financial outlook. Regularly reviewing these items can help observers understand the company’s evolving focus on transplant logistics, clinical services and acquisition-led growth within the U.S. healthcare ecosystem.
Strata Critical Medical (NASDAQ:SRTA) has completed the acquisition of Keystone Perfusion Services LLC for $124 million, representing a 9x multiple of 2025 estimated Adjusted EBITDA. The acquisition combines Strata's existing capabilities with Keystone's expertise in organ recovery and normothermic regional perfusion services.
Keystone is projected to generate $65 million in revenue and $13 million in Adjusted EBITDA for 2025, with revenue growth exceeding 50% compared to 2024. The deal structure includes 88% cash and 12% stock consideration, with potential earn-outs of up to $23 million based on performance through 2028.
Following the acquisition, Strata has updated its 2025 guidance to $180-190 million in revenue and $13-14 million in Adjusted EBITDA. If the acquisition had closed on January 1, 2025, the projected figures would be $225-235 million in revenue and $22-24 million in Adjusted EBITDA.
Strata Critical Medical (NASDAQ:SRTA), previously Blade Air Mobility (NASDAQ:BLDE), has announced its participation in the upcoming 2025 Jefferies Industrials Conference. The company's Co-CEO and CFO, Will Heyburn, will deliver a presentation on September 4, 2025, at 11:30 AM ET.
Investors can access the presentation via webcast, with a replay available afterward on the company's investor relations website at ir.stratacritical.com/news-events.
Strata Critical Medical (NASDAQ:SRTA), formerly Blade Air Mobility (NASDAQ:BLDE), has completed the sale of its Passenger business to Joby Aviation (NYSE:JOBY). The transaction includes stock-based upfront payment, with potential additional consideration of up to $35 million tied to employee retention and financial performance targets, plus up to $10 million in indemnity holdbacks.
The company has rebranded to focus exclusively on organ logistics and medical services, leveraging its coast-to-coast asset-light aircraft network. For FY2025, Strata projects revenue of $160-170 million with double-digit Adjusted EBITDA, and expects quarterly corporate expenses to decrease to $3.5 million by Q4 2025.